Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,762,882
  • Shares Outstanding, K 70,039
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,280 K
  • 60-Month Beta 0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 19.61
Trade AVXL with:

Options Overview

Details
  • Implied Volatility 152.49%
  • Historical Volatility 148.09%
  • IV Percentile 58%
  • IV Rank 34.52%
  • IV High 294.73% on 07/07/20
  • IV Low 77.51% on 01/04/21
  • Put/Call Vol Ratio 0.35
  • Today's Volume 5,100
  • Volume Avg (30-Day) 5,224
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 54,937
  • Open Int (30-Day) 32,270

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.14
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.06 +119.35%
on 05/25/21
27.85 -12.89%
on 06/21/21
+12.58 (+107.71%)
since 05/21/21
3-Month
10.01 +142.36%
on 05/13/21
27.85 -12.89%
on 06/21/21
+8.78 (+56.72%)
since 03/22/21
52-Week
3.65 +563.88%
on 09/08/20
28.70 -15.47%
on 02/04/21
+19.08 (+368.34%)
since 06/22/20

Most Recent Stories

More News
Thinking about buying stock in vTv Therapeutics, Score Media and Gaming, Bio-Path Holdings, Anavex Life Sciences, or Atossa Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTVT, SCR, BPTH, AVXL, and ATOS.

SCR : 25.39 (+14.01%)
VTVT : 2.42 (+2.54%)
ATOS : 7.22 (+22.58%)
AVXL : 23.95 (-4.85%)
BPTH : 6.73 (+5.27%)
Anavex Life Sciences Announces $50 Million Registered Direct Offering

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 23.95 (-4.85%)
Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, GSAT, RAPT, AYTU, and EVFM.

GSAT : 1.8000 (+19.21%)
EVFM : 1.1350 (-2.99%)
RAPT : 34.24 (-3.47%)
AVXL : 23.95 (-4.85%)
AYTU : 5.42 (-3.73%)
Anavex Life Sciences Announces ANAVEX(R)2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

ANAVEX(R)2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints RSBQ...

AVXL : 23.95 (-4.85%)
Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options

Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.

AVXL : 23.95 (-4.85%)
Company News for Jun 15, 2021

Companies In The News Are: RIDE, PHG, AVXL, RDS.A

RDS.A : 40.88 (+0.99%)
PHG : 50.70 (-0.69%)
AVXL : 23.95 (-4.85%)
RIDE : 10.10 (+0.30%)
Thinking about buying stock in Orphazyme, Corsair Gaming, Senseonics, Vaxart, or Anavex Life Sciences?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, CRSR, SENS, VXRT, and AVXL.

SENS : 3.32 (+2.79%)
CRSR : 31.52 (-1.22%)
ORPH : 5.97 (-8.44%)
VXRT : 7.65 (-3.16%)
AVXL : 23.95 (-4.85%)
Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX(R)2-73 (blarcamesine) and ANAVEX(R)3-71 (AF710B) related to the Treatment of Alzheimer's Disease

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 23.95 (-4.85%)
Thinking about trading options or stock in Wendy's, Workhorse Group, Dada Nexus, Anavex Life Sciences, or Virgin Galactic?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WEN, WKHS, DADA, AVXL, and SPCE.

DADA : 29.81 (+2.72%)
WEN : 23.19 (-1.57%)
AVXL : 23.95 (-4.85%)
WKHS : 14.04 (-3.44%)
SPCE : 38.90 (+8.00%)
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX(R)2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer's Disease

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 23.95 (-4.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 31.12
2nd Resistance Point 29.48
1st Resistance Point 27.33
Last Price 23.95
1st Support Level 23.54
2nd Support Level 21.90
3rd Support Level 19.75

See More

52-Week High 28.70
Last Price 23.95
Fibonacci 61.8% 19.13
Fibonacci 50% 16.18
Fibonacci 38.2% 13.22
52-Week Low 3.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar